Long-Acting Amylin Analog (Research Peptide)
Dragon Pharma Lyophilized Peptide
Dragon Pharma Cagrilintide 10 mg is supplied in a 2 mL vial and contains the long-acting amylin analog Cagrilintide at a labeled strength of 10 mg per vial. Product specifications, a published lab report, storage information, and other practical product details are provided below.
Labeled at 10 mg of Cagrilintide per vial.
Supplied as a lyophilized powder in a sealed, sterile 2 mL vial.
The product is presented as a freeze-dried powder requiring reconstitution before use.
A published lab report provides a measured result for the tested batch.
| Product name | Cagrilintide 10 mg |
|---|---|
| Active substance | Cagrilintide Acetate |
| Labeled strength | 10 mg/vial |
| Container | 2 mL vial |
| Product form | Lyophilized powder |
| Manufacturer | Dragon Pharma |
The latest published report for batch #CGDHD7, dated September 13, 2024, measured 9.39 mg against the stated 10 mg concentration. Open the Lab Reports tab to view the full report.
Other peptide products in the Dragon Pharma range include the amylin analog Mazdutide, the dual GIP/GLP-1 receptor agonist Survodutide, and the GLP-1 receptor agonist Semaglutide.
Each peptide has a distinct amino acid sequence and is studied for its specific biological activity.
Published Testing
A published lab report for Dragon Pharma Cagrilintide 10 mg is provided below with the test date, measured result and reported batch number. The result can be compared directly with the product's labeled strength of 10 mg/vial.
Science & Research
Cagrilintide is a long-acting analog of the naturally occurring hormone amylin. It is being investigated as a potential therapeutic for weight management.
Cagrilintide is a synthetic peptide that mimics the activity of the naturally occurring hormone amylin, which is co-secreted with insulin from the pancreas.
It acts as an agonist at amylin receptors in the hindbrain and hypothalamus, which are involved in appetite regulation and satiety signaling.
Cagrilintide is in Phase 3 clinical development by Novo Nordisk for the treatment of obesity and overweight, with data showing clinically meaningful weight loss.
Amylin is a 37-amino acid peptide that is co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Once secreted, it activates receptors in the hindbrain and hypothalamus to induce satiation, and it also impacts glucose control by suppressing glucagon secretion and delaying gastric emptying. Cagrilintide is a long-acting analog of human amylin that has been modified to improve its chemical stability and circulating half-life. It acts by binding to amylin receptors (AMY1-3) to suppress appetite and promote satiety.
The product is supplied as a lyophilized powder at a labeled strength of 10 mg per vial.
Cagrilintide is not an anabolic steroid or a hormone like testosterone or growth hormone. It is an investigational amylin analog with a mechanism of action distinct from these compounds, acting on appetite regulation through amylin receptors in the brain.
Cagrilintide is in Phase 3 clinical development for obesity and overweight. ClinicalTrials.gov provides study details and data on its safety and efficacy.
Important Health Information
Peptide products should be handled with appropriate care, particularly when being reconstituted for use.
Following the correct reconstitution procedure and using sterile handling techniques is essential to minimize the risk of contamination.
In clinical studies, common side effects of cagrilintide include nausea, vomiting, diarrhea, decreased appetite, and constipation. These are generally mild to moderate and often more pronounced during dose escalation.
Clinical data on the safety, efficacy, and appropriate dosing of this specific peptide is limited outside of formal clinical trials. The risk profile is not as well-defined as that of more established drugs.
As with any peptide or protein-based product, there is a potential for hypersensitivity. Discontinue use and seek medical advice if signs of an allergic reaction develop.
Discussing any new product, including peptide compounds, with a healthcare professional is recommended before use.
Cagrilintide is not intended to diagnose, treat, cure, or prevent any disease. It should be handled as a research compound. Individuals with known allergies to peptides should exercise caution.
The product should be stored securely to prevent accidental access or use by children or other household members.
As a peptide with limited established clinical use, its status under anti-doping rules may vary. Athletes should check the current WADA Prohibited List before competition.
Common Product Questions
Quick answers about Cagrilintide 10 mg specifications, the published lab report, storage, shipping, Bitcoin payment, and general product information.
Dragon Pharma Cagrilintide 10 mg is a lyophilized peptide product containing the long-acting amylin analog Cagrilintide at a labeled strength of 10 mg per vial. It is supplied in a sterile 2 mL vial.
Cagrilintide is a long-acting analog of the naturally occurring hormone amylin. It acts on amylin receptors in the brain to suppress appetite and induce satiety.
The product is supplied as a lyophilized powder in a 2 mL vial that requires reconstitution with a suitable diluent before use.
The published report, dated September 13, 2024, measured 9.39 mg for batch #CGDHD7. This corresponds to approximately 93.90% of the stated 10 mg concentration.
No. Each report applies to the sample submitted for that specific test and the batch identified in the report. It does not independently verify the content or condition of every individual vial.
Store the lyophilized powder in its original packaging at room temperature, protected from heat, moisture, and direct light. Once reconstituted, follow the storage instructions provided with the diluent.
No. Cagrilintide is a peptide that mimics the hormone amylin but does not act as an anabolic steroid or growth hormone.
As a peptide with limited established clinical use, its status under anti-doping rules may vary. Athletes should check the current WADA Prohibited List before competition.
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4β5 business days after dispatch, while shipments from the International Warehouse typically take 15β20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy Cagrilintide 10 mg with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Clinical study information is available from sources such as ClinicalTrials.gov. Direct links to relevant resources are provided in the Science & Research section above.